AJPH.NS
Latest Trade
979.55INRChange
-0.30(-0.03%)Volume
24,756Today's Range
-
985.9052 Week Range
-
1,204.45As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
Previous Close | 979.85 |
|---|---|
Open | 980.90 |
Volume | 24,756 |
3M AVG Volume | 1.91 |
Today's High | 985.90 |
Today's Low | 975.20 |
52 Week High | 1,204.45 |
52 Week Low | 825.00 |
Shares Out (MIL) | 87.70 |
Market Cap (MIL) | 85,476.77 |
Forward P/E | 20.36 |
Dividend (Yield %) | 1.79 |
India's Ajanta Pharma Sept-Quarter Profit Falls
India's Ajanta Pharma June-Qtr Consol PAT Rises
India's Ajanta Pharma March-Qtr Consol Profit Falls
Ajanta Pharma Limited is a holding company. The Company is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations. Its business includes branded generics in emerging markets of Asia and Africa, generics in the developed markets of the United States and Institutional sales. The branded generics business is spread in India and over 30 emerging countries across Africa, Commonwealth of Independent States (CIS), the Middle East and South East Asia. The Company serves a range of therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, orthopedics, pediatric, respiratory and general health products. Ajanta has six formulations manufacturing facilities located in India and 1 in Mauritius. In addition, the Company also has an API manufacturing facility located at Waluj, India. The Company's subsidiaries include Ajanta Pharma (Mauritius) Ltd., and Ajanta Pharma USA Inc.
Industry
Biotechnology & Drugs
Executive Leadership
Mannalal B. Agrawal
Non-Executive Chairman of the Board
Madhusudan B. Agrawal
Vice Chairman of the Board
Gaurang Shah
Compliance Officer, Senior General Manager - Legal, Company Secretary
Rajesh M. Agrawal
Joint Managing Director, Director
Yogesh M. Agrawal
Managing Director, Director
Price To Earnings (TTM) | 22.18 |
|---|---|
Price To Sales (TTM) | 3.79 |
Price To Book (MRQ) | 3.48 |
Price To Cash Flow (TTM) | 18.18 |
Total Debt To Equity (MRQ) | 3.06 |
LT Debt To Equity (MRQ) | 1.44 |
Return on Investment (TTM) | 15.68 |
Return on Equity (TTM) | 13.28 |
* MARCH QUARTER CONSOL PROFIT 944.9 MILLION RUPEES VERSUS PROFIT 1.14 BILLION RUPEES YEAR AGO
* SAYS FORMULATION FACILITY AT DAHEJ WAS INSPECTED BY US FDA FROM 5TH TO 9TH FEBRUARY
* DEC QUARTER CONSOL PROFIT 1.47 BILLION RUPEES VERSUS PROFIT 1.43 BILLION RUPEES YEAR AGO
* SAYS PURUSHOTTAM B. AGRAWAL RESIGNS AS VICE-CHAIRMAN Source text: http://bit.ly/2kuqxWC Further company coverage:
* Ajanta Pharma announces approval & launch of clonidine hydrochloride extended release tablets
* Sept quarter consol net profit 1.32 billion rupees versus 1.31 billion rupees year ago
* Says received the final approval for Entacapone tablets from US FDA
* Says launched eletriptan hydrobromide tablets in US market through our wholly owned subsidiary, Ajanta Pharma USA Inc. Source text for Eikon: Further company coverage:
* June quarter profit 947.9 million rupees versus 1.20 billion rupees year ago
* Says Ganga Exports has sold 2.7 million equity shares of company representing 3.07 pct of paid up capital Source text for Eikon: Further company coverage:
* March quarter consol net profit 1.14 billion rupees versus profit 1.09 billion rupees year ago
* Ajanta Pharma Ltd says co's Dahej facility was inspected by FDA from April 3-7, 2017; no form 483 was issued Source text: [This is to inform you that Company's formulation facility at Dahej was inspected by US FDA from 3rd to 7th April, 2017. At the end of the inspection...
* Says company's Paithan facility was recently inspected by US FDA and company has issued one procedural related 483.
* Dec quarter consol net profit 1.43 billion rupees versus profit 1.14 billion rupees year ago
* Ajanta Pharma clarifies on import alert received from USFDA
* Gets import alert from USFDA for its Aurangabad plant - FDA website
* Says Ajanta Pharma announces US FDA approval for Duloxetine Hydrochloride delayed release capsules
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.